Source: International Congress 2018 – Idiopathic interstital pneumonias other than idiopathic pulmonary fibrosis (IPF)
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
C. Hayton (Manchester, United Kingdom), H. Morris (Manchester, United Kingdom), T. Marshall (Manchester, United Kingdom), K. Zakis (Manchester, United Kingdom), T. Garfoot (Manchester, United Kingdom), P. Rivera Ortega (Manchester, United Kingdom), M. Greaves (Manchester, United Kingdom), C. Leonard (Manchester, United Kingdom), N. Chaudhuri (Manchester, United Kingdom). Antifibrotic choice in idiopathic pulmonary fibrosis. 2953

Member's Comments

No comment yet.

Related content which might interest you: Pirfenidone in idiopathic pulmonary fibrosis Source: Eur Respir J 2010; 35: 821-829 Year: 2010 Pirfenidone in idiopathic pulmonary fibrosis Source: Eur Respir J 2010; 36: 695-696 Year: 2010 Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis Source: Eur Respir Rev, 28 (153) 190022; 10.1183/16000617.0022-2019 Year: 2019 Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Comorbidities influence in idiopathic pulmonary fibrosis antifibrotic treatments Source: International Congress 2019 – Comorbidities of idiopathic pulmonary fibrosis Year: 2019 Pirfenidone treatment in idiopathic pulmonary fibrosis: too much of a great expectation Source: Eur Respir J 2012; 40: 794-795 Year: 2012 Idiopathic pulmonary fibrosis and pirfenidone Source: Eur Respir J 2010; 35: 728-729 Year: 2010 Pirfenidone treatment in idiopathic pulmonary fibrosis: An Italian case series Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Current and future therapeutic approaches in idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: 693-703 Year: 2005 Exacerbation of idiopathic pulmonary fibrosis Source: International Congress 2016 – Russia Session Year: 2016 PP217 – Modeling idiopathic pulmonary fibrosis on a lung-on-chip Source: ERS Lung Science Conference 2021 Year: 2021 Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients Source: International Congress 2016 – IPF pathogenesis Year: 2016 Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 A first step against idiopathic pulmonary fibrosis Source: Eur Respir Rev 2011; 20: 130-131 Year: 2011 Angiogenesis in idiopathic pulmonary fibrosis Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis Year: 2020 Pulmonary hypertension in idiopathic pulmonary fibrosis Source: Annual Congress 2010 - Clinical aspects in pulmonary fibrosis Year: 2010 Negative outcome of prednisone in possible idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF clinical Year: 2016